Ken Griffin Cellectis S.A. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$1.86 - $3.35 $5,208 - $9,380	2,800 New	2,800 $5,000
Q4 2023 Feb 14, 2024	SELL	$0.97 - $3.55 $2,425 - $8,875	-2,500 Reduced 83.33%	500 $1,000
Q3 2023 Nov 14, 2023	SELL	$1.58 - $2.86 $3,634 - $6,578	-2,300 Reduced 43.4%	3,000 $4,000
Q2 2023 Aug 14, 2023	BUY	$1.72 - $2.12 $9,116 - $11,236	5,300 New	5,300 $10,000
Q4 2022 Feb 14, 2023	BUY	$1.85 - $2.6 $1,295 - $1,820	700 New	700 $1,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $80.6M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.